International Business Machines Corporation (NYSE:IBM) posted a solid weekly gain of 6.09%, outperforming the Nasdaq Composite by 0.90 percentage point and the S&P 500 by 2.51 points. The rally came amid a broader market uptick fueled by softer U.S. jobs data, which eased concerns about further interest rate hikes. However, the advance was accompanied by a notable reduction in analyst price targets, signaling a cautious outlook from Wall Street.
According to data from MarketBeat, the consensus price target for IBM has dropped 13.3% over the past month to $265.40. Despite the lower target, the consensus rating remains a Moderate Buy, implying a potential upside of approximately 11.9% from Friday's closing price of $237.28. This divergence between price action and analyst sentiment suggests a repricing rather than a broad surrender among analysts.
The stock's recent performance is highlighted in Friday's cross-market summary. IBM closed at $237.28, up 1.65% on the day, but remains 28.6% below its June 2 high. Trading volume, however, was subdued, with average daily volume at 6.05 million shares, just 54.4% of the 65-day average. This suggests that the rebound may lack conviction, as volume often confirms price moves.
Investors are also preparing for the ex-dividend date on Monday. IBM will trade ex-dividend by $1.69, with the payout scheduled for September 10. Subtracting the dividend from Friday's closing price yields an adjusted reference price of $235.59. This adjustment is a routine occurrence and should not be interpreted as a negative signal.
Recent post-earnings ratings from various brokerages show a wide range of valuations. Susquehanna has a Neutral rating with a $225 target (implying -5.2%), while Barclays (NYSE:BCS) maintains an Overweight rating with a $262 target (+10.4%). Citigroup (NYSE:C) has a Buy rating with a $245 target (+3.3%), and Morgan Stanley (NYSE:MS) holds an Equalweight rating with a $190 target (-19.9%). Goldman Sachs (NYSE:GS) is the most bullish, with a Buy rating and a $270 target (+13.8%). The 27-analyst consensus stands at Moderate Buy with a $265.40 target.
The average target price has dropped by $40.88 over the past month. Buy ratings decreased from 16 to 15, while hold recommendations increased from nine to 11, and one sell rating emerged. This shift indicates a more cautious stance among analysts, though not a wholesale abandonment of the stock.
CFRA analyst Brooks Idlet attributed the decline in targets to "specific IBM-related hardware issues," noting that the quarter was less negative for the broader software sector. This suggests that IBM's challenges may be company-specific rather than indicative of industry-wide weakness.
Fundamentally, IBM's second-quarter performance remains a key focus. Revenue came in at $17.16 billion, 2.4% below the $17.58 billion estimate, while adjusted earnings per share of $2.93 missed by 1.3%. Software revenue of $7.76 billion was 1.5% under the estimate but grew 5% year-over-year. Infrastructure revenue fell 7.4% to $3.84 billion, with IBM Z dropping 42%. The company also lowered its 2026 constant-currency revenue growth outlook to 4%-5% from above 5%, while free-cash-flow growth guidance was maintained at about $1 billion year-over-year.
CEO Arvind Krishna expressed optimism, noting that roughly one-third of postponed deals were completed ahead of schedule during the third quarter. "A lot of the demand is deferred, not destroyed," he said, though investors are waiting to see this materialize in software and mainframe revenue.
Valuation-wise, IBM trades at a P/E ratio of 21.0, significantly lower than Microsoft's (NASDAQ:MSFT) 29.8 and Oracle's (NYSE:ORCL) 26.4, but higher than Accenture's (NYSE:ACN) 14.0. This places IBM between a consulting firm and a cloud growth company, reflecting its hybrid positioning.
Looking ahead, IBM has no investor events scheduled this week. The next earnings release is tentatively set for October 21. Key economic data includes Wednesday's CPI, Thursday's PPI, and Friday's retail sales report. Risks include further delays in postponed deals, customer preference for AI infrastructure over IBM software and mainframes, and the possibility that strong inflation numbers could drive yields higher and pressure valuations.
On Monday, total return will be more significant than the headline price. A decline of about $1.69 would primarily reflect the dividend adjustment. An increase in volume following this adjustment would provide a clearer signal that IBM's recovery is sustainable.
